Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma-Reference-Cited by-同舟云学术

Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma

Author:

Saburi Masuho¹,Ogata Masao²,Soga Yasuhiro³,Kondo Yoshiyuki⁴,Kurimoto Ryo¹,Itani Kazuhito¹,Kohno Kazuhiro¹,Uchida Hiroki⁵,Nakayama Toshiyuki¹

Affiliation:

1. Department of Hematology, Oita Kouseiren Tsurumi Hospital, Oita, Japan,

2. Department of Hematology, Oita University Hospital, Oita, Japan,

3. Department of Clinical Laboratory, Oita Kouseiren Tsurumi Hospital, Oita, Japan,

4. Department of Diagnostic Pathology, Oita Kouseiren Tsurumi Hospital, Oita, Japan,

5. Department of Nephrology, Oita Kouseiren Tsurumi Hospital, Oita, Japan.

Publisher

Japanese Society for Lymphoreticular Tissue Research

Subject

General Medicine

Link

Reference21 articles.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anaplastic Multiple Myeloma: Case Series and Literature Review;Asploro Journal of Biomedical and Clinical Case Reports;2022-01-15